Company Lumos Diagnostics Holdings Limited

Equities

LDX

AU0000157091

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Quarterly revenue - Rate of surprise

Sector Diagnostic & Testing Substances

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-04-19 am EDT			5-day change	1st Jan Change
0.056 ^AUD	-1.75%		-11.11%	-23.29%

Apr. 09	Lumos Diagnostics' FebriDx May Help Optimize Antibiotic Use in Children with Febrile Respiratory Infections, Study Shows	MT
Feb. 27	Lumos Diagnostics Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Lumos Diagnostics Holdings Ltd is an Australia-based company, which specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes, Lumos-branded POC tests that target infectious and inflammatory diseases. The Company's products include FEBRIDX, COVIDX, and ViraDx. FebriDx is a point-of-care test which can be used to detect and aid in differentiating bacterial from viral acute respiratory infections. ViraDx is a point-of-care, three-in-one COVID-19/Flu A/Flu B rapid antigen test. Its services include assay development, reader development, cloud and data, and manufacturing. It manages the full development program for point-of-care (POC) assays, from sourcing and/or generation of reagents, right through to verification and validation.

AUD in Million	2022	Weight	2023	Weight	Delta
Services 97.1 %	8	66.6 %	10	97.1 %	+32.04%
Point of Care Diagnostics 2.9 %	4	33.4 %	0	2.9 %	-92.22%

AUD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	11	95.8 %	11	100.0 %	-5.46%

Managers	Title	Age	Since
Douglas Ward CEO	Chief Executive Officer	-	22-06-20
Barrie Lambert DFI	Director of Finance/CFO	-	22-02-15
Sam Lanyon CHM	Chairman	-	18-12-31
Jonathan Gary CTO	Chief Tech/Sci/R&D Officer	-	20-12-31
Annie Bell CTO	Chief Tech/Sci/R&D Officer	-	17-12-31
Sacha Dopheide CTO	Chief Tech/Sci/R&D Officer	-	18-12-31
Jason Inman CTO	Chief Tech/Sci/R&D Officer	-	-
Matthijs Smith IRC	Investor Relations Contact	-	-
Huan Tran PRN	Corporate Officer/Principal	-	-
Sarah Glubka HRO	Human Resources Officer	-	16-12-31

Members of the board	Title	Age	Since
Lawrence Mehren BRD	Director/Board Member	57	20-10-31
Bronwyn Le Grice BRD	Director/Board Member	-	20-10-31
Douglas Ward CEO	Chief Executive Officer	-	22-06-20
Catherine Robson BRD	Director/Board Member	-	20-11-30
Sam Lanyon CHM	Chairman	-	18-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	481,300,042	335,503,301 ( 69.71 %)	0	69.71 %

Name	Equities	%	Valuation
Planet Innovation Holdings Ltd. 14.13 %	68,021,060	14.13 %	3 M $
Perennial Value Management Ltd. 13.64 %	65,644,275	13.64 %	3 M $
Lumos Diagnostics 8.337 %	40,124,915	8.337 %	2 M $
RYDER CAPITAL LIMITED 5.319 %	25,601,613	5.319 %	1 M $
The Lind Partners LLC 3.428 %	16,500,000	3.428 %	656 700 $
Douglas Ward 0.0987 %	475,000	0.0987 %	18 905 $

Lumos Diagnostics Holdings Ltd.

100 Albert Road Level 4

3205, South Melbourne

http://www.lumosdiagnostics.com

address Lumos Diagnostics Holdings Limited(LDX)

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
LUMOS DIAGNOSTICS HOLDINGS LIMITED	-23.29%	17.67M
BIOMÉRIEUX	-1.39%	12.47B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-17.62%	6.99B
DIASORIN S.P.A.	-3.15%	5.1B
LANTHEUS HOLDINGS, INC.	+0.53%	4.27B
AUTOBIO DIAGNOSTICS CO., LTD.	-6.68%	4.27B
10X GENOMICS, INC.	-48.27%	3.45B
ANDON HEALTH CO., LTD.	+7.09%	2.61B
VITROLIFE AB	-14.84%	2.08B
MYRIAD GENETICS, INC.	-3.40%	1.67B

Diagnostic & Testing Substances